Tempus AI (TEM) Projected to Post Earnings on Tuesday

Tempus AI (NASDAQ:TEM) is anticipated to release its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $362.5520 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Tempus AI Trading Down 2.7%

Shares of NASDAQ:TEM opened at $58.37 on Friday. The stock has a 50 day moving average of $62.35 and a 200 day moving average of $73.50. The company has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI has a 12-month low of $36.22 and a 12-month high of $104.32.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TEM shares. BTIG Research upped their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Piper Sandler dropped their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Needham & Company LLC increased their price target on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Finally, Mizuho initiated coverage on Tempus AI in a research note on Thursday. They issued an “outperform” rating and a $100.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and a consensus target price of $85.92.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Insider Transactions at Tempus AI

In related news, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total value of $1,461,511.20. Following the completion of the transaction, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. This trade represents a 15.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 775,159 shares of company stock valued at $50,789,800 over the last quarter. 26.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC bought a new stake in Tempus AI in the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Tempus AI during the third quarter valued at approximately $38,000. EverSource Wealth Advisors LLC boosted its position in shares of Tempus AI by 88.8% during the second quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock valued at $44,000 after buying an additional 325 shares during the period. Finally, Danske Bank A S bought a new position in shares of Tempus AI during the third quarter valued at approximately $48,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.